Order Entry
Puerto Rico
ContactUsLinkComponent
Human Recombinant VEGFA (from E. coli)
Human Recombinant VEGFA (from E. coli)
Catalog # RL009-001-B99
Minority or Woman-Owned Business Enterprise
Small Business Enterprise
CAS Number:  
Human Recombinant VEGFA (from E. coli)
Catalog # RL009-001-B99
Supplier Number:  009-001-B99
Minority or Woman-Owned Business Enterprise
Small Business Enterprise
CAS Number:  

Specifications

  • Protein/Peptide Type:
    Recombinant
  • Source:
    E. coli
  • Species:
    Human
  • Size:
    10 µg
  • Storage Conditions:
    Store vial at 4 °C prior to restoration. Dilute only prior to immediate use. Maintain sterility. This product DOES NOT contain preservative. DO NOT VORTEX. We recommend adding a carrier protein such as HSA or BSA to 0.1% (i.e. 1.0 mg/mL) . For best results aliquot contents and freeze at –20 °C or colder. Avoid cycles of freezing and thawing. Centrifuge vial before each opening to dislodge contents from the cap and to clarify if contents are not clear after standing at room temperature.
  • Endotoxin Content:
    Measured by LAL is <0.01ng/µg or <0.1EU/µg.
  • Biological Activity:
    Human recombinant VEGF-165 is fully biologically active when compared to standards. The ED50, as determined by the dose dependent induction of HUVEC proliferation, is 3.1-4.6 ng/ml.
  • Gene ID:
    P15692-11
  • Reconstitution Instructions:
    100 µL
  • Protein Synonyms:
    VEGF-A165 cytokine|VPF-165|Vascular endothelial growth factor A-165|Vascular permeability factor
  • Protein/Peptide Name:
    VEGFA
  • Purity:
    >95%
  • Formulation:
    Lyophilized
  • Shipping Temperature:
    Ambient
  • Cat. No.:
    RL009-001-B99
  • Supplier no.:
    009-001-B99

Specifications

About this item

Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as Tumor Angiogenesis Factor or Vascular Permeability Factor. Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating vasolidation via nitric oxide-dependent pathways. Alternative splicing of the mRNA for VEGF-A results in several isoforms of the protein being produced. Rat and bovine VEGF are one amino acid shorter than the human factor, and the bovine and human sequences show a homology of 95 percent.

In contrast to other factors mitogenic for endothelial cells such as FGF-1, FGF-2 and PDGF, VEGF is synthesized as a precursor containing a typical hydrophobic secretory signal sequence of 26 amino acids. Glycosylation is not required for efficient secretion of VEGF. Recombinant Human VEGF produced in E.coli is a double, non-glycosylated, polypeptide chain containing 165 amino acids and having a molecular mass of 38231 Daltons.